HK$210.60
6.63%
Hong Kong, Sep 21, 03:46 pm HKT. Closed.
Why the stock moved Why the stock moved Beta
ISIN
KYG2929M1087
Symbol
9606

Duality Biotherapeutics Inc Stock price

HK$211.40
+16.90 8.69% 1M
-58.40 21.65% 6M
-86.80 29.11% YTD
-175.60 45.37% 1Y
+116.80 123.47% 3Y
+116.80 123.47% 5Y
+116.80 123.47% 10Y
+116.80 123.47% 20Y
Hong Kong, Closing price Mon, Sep 21 2026
+13.90 7.04%
ISIN
KYG2929M1087
Symbol
9606
Industry

Is Duality Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$16.7b
Enterprise Value
HK$12.9b
Net debt
positive
Cash
HK$4.0b
Shares outstanding
89.4m
Valuation (TTM | estimate)
P/E
negative
P/S
7.7 | 8.5
EV/Sales
6.0 | 6.6
EV/FCF
61.1
P/B
5.9
Financial Health
Equity Ratio
62.3%
Return on Equity
-106.9%
ROCE
-15.9%
ROIC
116.8%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
HK$2.2b | HK$2.0b
EBITDA
HK$-524.9m
EBIT
HK$-529.7m
Net Income
HK$-3.0b
Free Cash Flow
HK$211.9m
Growth (TTM | estimate)
Revenue
- | -9.2%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
31.8%
EBITDA
-24.2%
EBIT
-24.4%
Net
-140.1%
Free Cash Flow
9.8%
More
EPS
HK$-33.5
FCF per Share
HK$2.4
Short interest
-
Employees
231
Rev per Employee
HK$9.4m

Duality Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Duality Biotherapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Duality Biotherapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Duality Biotherapeutics Inc

Dec '25
+/-
%
2,170 2,170
-
100%
- Direct Costs 1,479 1,479
-
68%
690 690
-
32%
- Selling and Administrative Expenses 251 251
-
12%
- Research and Development Expense 977 977
-
45%
-525 -525
-
-24%
- Depreciation and Amortization 4.87 4.87
-
0%
EBIT (Operating Income) EBIT -530 -530
-
-24%
Net Profit -3,040 -3,040
-
-140%

In millions HKD.

Don't miss a Thing! We will send you all news about Duality Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Duality Biotherapeutics, Inc. operates as a clinical stage company. The company is headquartered in Shanghai, Shanghai and currently employs 231 full-time employees. The company went IPO on 2025-04-15. The firm is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The firm's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The firm's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The firm principally conducts its businesses in domestic and overseas markets.

Head office Cayman Islands
Employees 231
Website www.dualitybiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today